MASLD/MASH Learning Center
Identifying MASLD Patients
October 2026
In this educational video, Gabriella McCarty, a nurse practitioner with Oshi Health specializing in gastroenterology, inflammatory bowel disease, and hepatology, discusses the evolving landscape of metabolic dysfunction-associated steatotic liver disease (MASLD) diagnosis, risk assessment, and treatment. As advancements in MASLD management continue to reshape clinical practice, Gabriella emphasizes the importance of looking beyond hepatic steatosis, or fatty liver, to identify patients at risk for liver fibrosis, disease progression, and metabolic complications. She explores why liver enzyme levels alone may not accurately reflect the severity of liver fibrosis and highlights the role of the FIB-4 score as a practical, noninvasive tool for initial fibrosis risk assessment in primary care and gastroenterology settings. Gabriella also discusses the importance of evaluating metabolic risk factors, including obesity, insulin resistance, type 2 diabetes, hypertension, hyperlipidemia, and cardiovascular disease, when developing a comprehensive approach to MASLD management. With emerging treatment options expanding beyond traditional lifestyle modifications, she encourages GI and primary care clinicians to take a proactive, individualized approach to identifying at-risk patients, assessing liver health, and determining when further evaluation or specialist referral may be necessary. Learn how advanced practice providers (APPs) and other healthcare professionals can improve early detection, risk stratification, and management of MASLD to help prevent progression to metabolic dysfunction-associated steatohepatitis (MASH) and advanced liver disease.
Watch Now
Backbone of MASH: Diet & Exercise
October 2026
In this educational video, Christie Morrison, Medical Education Lead at Oshi Health, discusses how advanced practice providers (APPs) can help patients with metabolic dysfunction-associated steatotic liver disease (MASLD) implement sustainable dietary and lifestyle modifications to reduce liver fat, improve metabolic health, and potentially prevent progression to metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, and cirrhosis. Christie highlights practical, patient-centered strategies for MASLD and MASH management, including incorporating lean proteins, whole grains, fruits, vegetables, and healthy fats while reducing added sugars, processed foods, and red meat consumption. She also explores the potential liver health benefits of coffee consumption, the importance of regular physical activity, and how individualized exercise prescriptions can encourage long-term behavioral changes. Emphasizing the role of APPs in patient education, Christie shares actionable approaches to setting realistic goals, overcoming barriers to lifestyle modifications, and leveraging registered dietitians and community resources to support patients with MASLD. Learn how APPs can empower patients to make manageable, lasting lifestyle changes that support liver health and help reduce the risk of MASH progression.
Watch Now
MASLD Management With F0–F1 Fibrosis
August 2026
In this MASLD Community Network podcast, Valerie Shin, nurse practitioner at UCLA Health Liver Clinic, and Sherona Bau, hepatology nurse practitioner at UCLA Health, discuss the management of metabolic dysfunction-associated steatohepatitis (MASH) in patients with minimal or no liver fibrosis, classified as F0–F1. They explain why fibrosis staging is essential for assessing prognosis, determining medication eligibility, and developing an appropriate monitoring plan. The conversation highlights lifestyle modification as the foundation of MASH treatment, including sustainable weight loss, gradual increases in physical activity, strength training, Mediterranean-style nutrition, portion control, reduced intake of sugary drinks and ultra-processed foods, and alcohol avoidance. Valerie and Sherona also share practical strategies for reducing sedentary time, managing diabetes, high blood pressure, cholesterol, obesity, and sleep apnea, and lowering the cardiovascular risks associated with fatty liver disease. Viewers will gain actionable guidance on weight-loss goals, exercise recommendations, dietitian support, coffee and statin use, and repeat noninvasive fibrosis testing to help prevent MASH progression and support long-term liver and metabolic health.
Watch Now
Ins & Outs of MASLD
August 2026
In this MASH-focused podcast, Renee Pozza, nurse practitioner, and Anna Hefner of Southern California GI and Liver Centers discuss how healthcare professionals can screen, risk-stratify, treat, and monitor patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The conversation reviews the evolving terminology from NAFLD and NASH to MASLD and MASH, the relationship between fatty liver disease and metabolic risk factors such as obesity, type 2 diabetes, hypertension, high cholesterol, elevated triglycerides, sleep apnea, and cardiovascular disease, and the importance of assessing alcohol use. The speakers explain how FibroScan or vibration-controlled transient elastography, magnetic resonance elastography, FIB-4, ELF testing, laboratory studies, and metabolic assessments can help identify patients with clinically significant F2–F3 liver fibrosis who may benefit from treatment. They also examine the roles of GLP-1 therapy and resmetirom, medication tolerability, statin management, insurance authorization, and individualized treatment sequencing. Additional topics include culturally responsive nutrition counseling, sustainable exercise strategies, side-effect management, follow-up laboratory testing, repeat fibrosis assessment, and hepatocellular carcinoma surveillance in patients with advanced fibrosis. Viewers will gain practical insights into combining medication, diet, physical activity, metabolic risk reduction, and ongoing patient communication to prevent fibrosis progression and improve long-term liver health.
Watch Now
Prognosis of MASLD
August 2026
In this MASH Community Network podcast, Jonathan Yeh, a liver physician assistant with the Center for Liver Disease and Transplantation at Columbia University in New York City, reviews prognosis in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The presentation explains why fibrosis stage is the strongest predictor of liver-related outcomes, including progression to advanced fibrosis, cirrhosis, portal hypertension, hepatic decompensation, hepatocellular carcinoma, and liver transplantation. Jonathan also discusses the competing risks of cardiovascular disease and malignancy, particularly in patients with F0–F2 fibrosis, and highlights important risk factors for disease progression, including type 2 diabetes, insulin resistance, obesity, visceral adiposity, sarcopenia, metabolic syndrome, sleep apnea, chronic kidney disease, alcohol use, and genetic susceptibility. Viewers will learn why normal ALT levels do not rule out advanced liver disease and how noninvasive liver testing—including vibration-controlled transient elastography (VCTE or FibroScan), the Enhanced Liver Fibrosis (ELF) test, and magnetic resonance elastography (MRE)—can support fibrosis staging, longitudinal monitoring, and clinical decision-making. The episode also outlines how advanced fibrosis and cirrhosis change surveillance strategies, including evaluation for portal hypertension, variceal screening, HCC surveillance, metabolic risk reduction, and ongoing reassessment of fibrosis progression.
Watch Now
Podcast: Best Practices For MASH Patient Identification
April 2026
Stay up to date on MASH and MASLD with expert insights from nurse practitioners Sarah Dawkins of Duke University Medical Center and Edith Johannes of UCLA Health. This episode focuses on best practices for identifying at-risk patients, including those with steatosis on imaging, cardiometabolic risk factors, and elevated BMI—highlighting why early screening is critical to preventing progression to cirrhosis and liver transplant. Learn how to apply practical, non-invasive tools like FIB-4 and FibroScan to assess fibrosis risk, when to refer patients, and how to navigate common challenges such as intermediate scores and normal liver labs. With MASH becoming a leading cause of liver disease, this discussion provides actionable strategies for advanced practice providers and primary care clinicians to improve early detection and patient outcomes. Visit the GHAPP Digital Hub and GHAPP ACE app for more educational content.
Watch Now
Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?
April 2026
Learn how to effectively support patients starting treatment for MASH with this practical, clinician-focused discussion featuring expert advanced practice providers. In this episode, hepatology specialists Robin Soto and Alison Moe break down how to set realistic expectations, define meaningful treatment goals beyond the scale, and guide patients through long-term lifestyle and pharmacologic management. Discover why success in MASH care extends beyond weight loss to include improvements in A1C, lipid profiles, energy levels, sleep, and overall metabolic health, and how shifting the conversation away from numbers can improve patient motivation and adherence. This episode also explores how to structure patient journeys through the first 30, 60, and 90 days of treatment, navigate common challenges with compliance, and reinforce sustainable behavior change. Gain insights into emerging therapies, including newly approved medications targeting liver fat and fibrosis, as well as GLP-1 receptor agonists that support both metabolic health and liver outcomes. The discussion highlights how to personalize treatment plans, manage side effects, and empower patients to take control of their disease while preventing progression to cirrhosis and liver-related complications.
Watch Now
Lessons Learned in 2025 MASLD Care
February 2026
In this video, Michelle Barnett, PA-C, a hepatology physician assistant in Colorado Springs, reflects on key lessons learned in the evolving management of MASLD and MASH as we enter 2026. She clarifies updated terminology distinguishing MASLD and MASH from MetALD, helping primary care clinicians better identify patients with metabolic risk factors with and without regular alcohol use. The discussion highlights the impact of the November 2025 updates from American Association for the Study of Liver Diseases, which aim to improve disease awareness, risk stratification, and earlier referral. Michelle also shares real-world clinical experience with liver-directed therapy, including outcomes observed after more than a year of treatment with resmetirom, and reviews the FDA approval of semaglutide for patients with F2–F3 fibrosis, setting the stage for future combination therapy. The video reinforces lifestyle modification as the foundation of long-term MASLD management, outlining evidence-based recommendations for weight loss, exercise, and dietary interventions such as the Mediterranean diet. This practical update provides clinicians with actionable insights into current and emerging strategies for managing steatotic liver disease and staying current as guidelines continue to evolve.
Watch Now
Cardiovascular Disease in Patients With MASLD/MASH
February 2026
This video explores the critical relationship between cardiovascular disease and patients with MASLD and MASH, highlighting why cardiovascular risk—not liver failure—is the leading cause of mortality in this population. Oyin Penny, NP, discusses the importance of aggressive risk factor management, including lipid control, blood pressure optimization, and glucose management, and reframes these strategies as liver-protective therapies. The discussion emphasizes the need for a multidisciplinary approach to care and clarifies the safety and benefits of statin therapy in MASLD and MASH, including their role in reducing cardiovascular risk and hepatic inflammation. The video also reviews important drug–drug interactions, specifically how resmetirom can affect statin metabolism through CYP2C8 inhibition and why statin dose adjustments may be necessary. This practical overview reinforces that MASLD is not a reason to avoid statins—but a reason to prescribe them—and provides actionable insights for clinicians managing cardiometabolic risk in patients with fatty liver disease.
Watch Now
Alcohol and MASLD/MASH: Navigating the Complex Relationship
November 2025
In this insightful session from the GHAPP MASLD Community Network, Alison Moe, PA-C, dives into the complex and often misunderstood relationship between alcohol use and metabolic dysfunction–associated steatotic liver disease (MASLD). Drawing from clinical experience, Alison explains why accurately screening, quantifying, and discussing alcohol consumption with patients is essential to understanding disease progression, treatment eligibility, and overall liver health. She outlines how continued alcohol use can alter liver function tests (LFTs), confound noninvasive test results, and affect candidacy for emerging MASH pharmacotherapies. Viewers will learn how to approach sensitive conversations about drinking habits without stigma, interpret AASLD alcohol threshold guidelines, and apply effective counseling strategies for patients with combined alcohol-related and metabolic liver disease. Alison also discusses the role of PEth urine testing, lifestyle counseling, and the importance of complete abstinence for those with advanced fibrosis. This educational talk provides clinicians with actionable insights to support patients in improving their metabolic and liver health through honest communication, behavioral change, and evidence-based management.
Watch Now
NITs: A Practical Overview: Navigating the Basics
November 2025
Learn how non-invasive testing (NITs) is transforming fibrosis assessment in patients with MASLD and MASH. In this educational talk, Sarah Dawkins, FNP-C, MSN, RN from Duke University Liver Clinic, breaks down the differences between simple steatosis (MASLD) and steatohepatitis (MASH), explains when and how to use serum-based tests like FIB-4 and ELF, and explores the advantages and limitations of imaging tests such as FibroScan and MRI elastography. Discover how to interpret results, avoid false positives, and determine when hepatology referral or biopsy is needed. Perfect for clinicians managing metabolic liver disease and looking to integrate non-invasive testing into everyday practice.
Watch Now
Motivational Interviewing: Practical Techniques For Lifestyle Adherence
November 2025
In this engaging session from the GHAPP MASLD Community Network, Erin Tanner, DNP, from Gastro Health in Birmingham, Alabama, discusses how motivational interviewing can empower patients with fatty liver disease to make meaningful lifestyle changes. Drawing from over 14 years of experience in hepatology and gastroenterology, Erin explains how a collaborative, patient-centered approach can improve adherence to diet, exercise, and weight management plans. Using the RULE framework—Resist the righting reflex, Understand motivation, Listen with empathy, and Empower the patient—she demonstrates practical ways to foster trust and promote behavior change without judgment. Erin also introduces the SMART goals method (Specific, Measurable, Achievable, Relevant, Time-bound), guiding clinicians on how to set realistic, personalized goals that patients can achieve and sustain. Through reflective listening, affirmation, and consistent follow-up, providers can help patients overcome ambivalence, build confidence, and stay motivated on their journey to better liver and metabolic health.
Watch Now